特布他林吸入对 3 公里跑步计时赛表现的影响。
The Effects of Inhaled Terbutaline on 3-km Running Time-Trial Performance.
出版信息
Int J Sports Physiol Perform. 2019 Jul 1;14(6):822–828. doi: 10.1123/ijspp.2018-0633.
Terbutaline is a prohibited drug except for athletes with a therapeutic use exemption certificate; terbutaline's effects on endurance performance are relatively unknown. To investigate the effects of 2 therapeutic (2 and 4 mg) inhaled doses of terbutaline on 3-km running time-trial performance. A total of 8 men (age 24.3 [2.4] y; weight 77.6 [8] kg; and height 179.5 [4.3] cm) and 8 women (age 22.4 [3] y; weight 58.6 [6] kg; and height 163 [9.2] cm) free from respiratory disease and illness provided written informed consent. Participants completed 3-km running time trials on a nonmotorized treadmill on 3 separate occasions following placebo and 2- and 4-mg inhaled terbutaline in a single-blind, repeated-measures design. Urine samples (15 min postexercise) were analyzed for terbutaline concentration. Data were analyzed using 1-way repeated-measures analysis of variance, and significance was set at < .05 for all analyses. No differences were observed for completion times (1103 [201] s, 1106 [195] s, 1098 [165] s; = .913) for the placebo or 2- and 4-mg inhaled trials, respectively. Lactate values were higher ( = .02) after 4 mg terbutaline (10.7 [2.3] mmol·L) vs placebo (8.9 [1.8] mmol·L). Values of forced expiratory volume in the first second of expiration (FEV) were greater after inhalation of 2 mg (5.08 [0.2]; = .01) and 4 mg terbutaline (5.07 [0.2]; = .02) compared with placebo (4.83 [0.5] L) postinhalation. Urinary terbutaline concentrations were mean 306 (288) ng·mL and 435 (410) ng·mL ( = .2) and peak 956 ng·mL and 1244 ng·mL after 2 and 4 mg inhaled terbutaline, respectively. No differences were observed between the male and female participants. Therapeutic dosing of terbutaline does not lead to an improvement in 3-km running performance despite significantly increased FEV. The findings suggest that athletes using inhaled terbutaline at high therapeutic doses to treat asthma will not gain an ergogenic advantage during 3-km running performance.
特布他林是一种禁用药物，除了有治疗用途豁免证明的运动员；特布他林对耐力表现的影响相对未知。 研究 2 种治疗（2 和 4mg）吸入剂量的特布他林对 3 公里跑步计时赛表现的影响。 共有 8 名男性（年龄 24.3[2.4]岁；体重 77.6[8]kg；身高 179.5[4.3]cm）和 8 名女性（年龄 22.4[3]岁；体重 58.6[6]kg；身高 163[9.2]cm）无呼吸道疾病和疾病，提供了书面知情同意书。参与者在 3 次单独的情况下，在非机动跑步机上完成了 3 公里跑步计时赛，分别使用安慰剂和 2 毫克和 4 毫克吸入特布他林，采用单盲、重复测量设计。尿样（运动后 15 分钟）用于分析特布他林浓度。数据使用单向重复测量方差分析进行分析，所有分析的显著性水平均为<0.05。 安慰剂或 2 毫克和 4 毫克吸入试验的完成时间（分别为 1103[201]s、1106[195]s、1098[165]s； = .913）无差异。与安慰剂（8.9[1.8]mmol·L）相比，特布他林 4mg 后乳酸值更高（ = .02）（10.7[2.3]mmol·L）。呼气第一秒用力呼气量（FEV）值在吸入 2 毫克（5.08[0.2]； = .01）和 4 毫克特布他林（5.07[0.2]； = .02）后大于安慰剂（4.83[0.5]L）。吸入特布他林后，尿液中特布他林浓度的平均值分别为 306（288）ng·mL 和 435（410）ng·mL（ = .2）和峰值 956ng·mL 和 1244ng·mL，分别为 2 和 4mg 吸入特布他林。男性和女性参与者之间没有差异。 尽管 FEV 显著增加，但特布他林的治疗剂量并未导致 3 公里跑步成绩的提高。研究结果表明，使用高治疗剂量吸入特布他林治疗哮喘的运动员在 3 公里跑步表现中不会获得运动优势。
Zotero 插件